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Background: The Beijing strain of Mycobacterium tuberculosis (M. tb) has been most
frequently isolated from TB patients in South Korea, and the hyper-virulent Beijing/K
genotype is associated with TB outbreaks. To examine the diagnostic potential of Beijing/
K-specific peptides, we performed IFN-g release assays (IGRA) using a MTBK antigen
tube containing Beijing/K MTBK_24800, ESAT-6, and CFP-10 peptides in a cohort
studied during a school TB outbreak.
Methods: A total of 758 contacts were investigated for M. tb infection, and 43 contacts
with latent TB infection (LTBI) and 25 active TB patients were enrolled based on serial
screening with QuantiFERON-TB Gold In-Tube tests followed by clinical examinations.
Blood collected in MTBK antigen tubes was utilized for IGRA and multiplex cytokine bead
arrays. Immune responses were retested in 24 patients after TB treatment, and disease
progression was investigated in subjects with LTBI.
Results: Total proportions of active disease and LTBI during the outbreak were 3.7% (28/
758) and 9.2% (70/758), respectively. All clinical isolates had a Beijing/K M. tb genotype.
IFN-g responses to the MTBK antigen identifiedM. tb infection and distinguished between
active disease and LTBI. After anti-TB treatment, IFN-g responses to the MTBK antigen
were significantly reduced, and strong TNF-a responses at diagnosis were dramatically
decreased.
Conclusions: MTBK antigen-specific IFN-g has diagnostic potential for differentiating M.
tb infection from healthy controls, and between active TB and LTBI as well. In addition,
TNF-a is a promising marker for monitoring therapeutic responses. These data provide
informative readouts for TB diagnostics and vaccine studies in regions where the Beijing/K
strain is endemic.
Keywords: Beijing/K strain, cytokine, IFN-g release assay, latent tuberculosis infection, Mycobacterium
tuberculosis, outbreakgy | www.frontiersin.org March 2021 | Volume 11 | Article 5993861
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The Beijing family of Mycobacterium tuberculosis (M. tb) is a
predominant genotype in East Asia, with hyper-virulence and
rapid transmission (Glynn et al., 2002). It has been reported as an
important risk factor for treatment failure or relapse of
tuberculosis (TB) (Burman et al., 2009). The Beijing strains
have caused large outbreaks of TB and extensive spread of
multi-drug resistant TB in several countries (Glynn et al., 2002;
Gurjav et al., 2016). South Korea is an intermediate TB burden
country, with 66 cases per 100,000 population reported in 2018
(WHO, 2018). About 70% of clinical isolates in South Korea
belong to the Beijing family, and Beijing/K was identified as a
predominant Beijing genotype that causes pulmonary TB
outbreaks (Kim et al., 2001). The Beijing/K strain of M. tb
rapidly replicates and demonstrates severe pathogenic features
at an early stage of infection in mice compared withM. tbH37Rv
(Kim et al., 2017). Whole genome sequencing of the Beijing/K
strain revealed a 6-kDa early secretory antigenic target (ESAT-
6)-like protein, MTBK_24800 (GenBank accession no.
AIB49024.1), within the 5.7-kb insertion region compared with
the H37Rv (Han et al., 2015; Hur et al., 2016). More than 95%
identical amino acid sequences were found in other clinical
isolates, such as GuangZ0019 and CDC1551, which are super-
extensively drug resistant and have been highly transmissible
during outbreaks in China and USA (Valway et al., 1998; Lin
et al., 2013; Hur et al., 2016). However, there is no sequence
similarity to genes in M. bovis Bacillus Calmette–Guérin (BCG;
Pasteur 1173P2, Denmark 1331, Moreau RDJ) and
nontuberculous mycobacteria (NTM), such as M. avium and
M. marinum (Hur et al., 2016). Diagnostic values of IFN-g
responses induced by recombinant MTBK_24800 protein were
demonstrated by differentiating M. tb-infected groups from
healthy controls (Hur et al., 2016). Several epitope sites of
MTBK_24800 were predicted and the predominant epitope site
was found at C-terminal amino acids (76-99) in active TB
patients (Hur et al., 2016).
A third of the population in South Korea has latent TB
infection (LTBI) although the prevalence of LTBI has gradually
decreased: 59.3%, 44.4%, and 33.2% in 1975, 1990, and 2016,
respectively (Cho, 2018). Remarkable decrease of LTBI
prevalence was reported in the younger population: 6.5% and
10.9% in the ages 10 to 19 and 20 to 29, respectively (Yeon et al.,
2018). Based on recent surveillance data using Interferon (IFN)-g
release assays (IGRA), the estimated prevalence among first
grade high school students (mean age 15.3) was 2.1% (Yeon
et al., 2018). The IGRA such as QuantiFERON-TB Gold In-Tube
(QFT-GIT) test is used to screen TB contacts for M. tb infection
in the field. This commercial IGRA using ESAT-6 and 10 kDa-
culture filtrate protein (CFP-10) is advantageous compared to
the conventional tuberculin skin test because it has no cross-
reactivity with M. bovis BCG vaccination or infection with most
NTM (Pai et al., 2014). However, its variable outcome in the
borderline range of cut-off points (Metcalfe et al., 2013; Jonsson
et al., 2017) and insufficient differentiation between active TB
and LTBI (Hur et al., 2016) suggest the need for an improved
antigen-specific biomarker.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 2Here, we report the investigation of a recent TB outbreak that
occurred from September to November 2017 among students at
a high school in South Korea. Case detection and contact tracing
were performed by clinical evaluation, chest radiography, and
QFT-GIT test. Based on epidemiologic investigation, contacts
with active disease and LTBI were enrolled to examine IFN-g
responses induced by M. tb using Beijing/K-specific
MTBK_24800 and ESAT6/CFP-10 peptides. The potential
diagnostic values of 6 selected peptides, two from each antigen,
were assessed compared to the commercial QFT-GIT peptide
pool, and the antigen-specific IFN-g responses were followed up
in patients with TB after treatment. IFN-a, interleukin (IL)-13,
IL-17, C-X-C motif chemokine 10 (CXCL10), C-C Motif
Chemokine Ligand 5 (CCL5), and tumor necrosis factor
(TNF)-a were also measured.MATERIALS AND METHODS
Epidemiologic Investigation and Enrolment
of Study Subjects
The first index case developed a productive cough and fever in
July 2017. He had been treated for Mycoplasma pneumonia but
was finally diagnosed as having sputum smear positive-
pulmonary TB in September 2017. As two additional active TB
cases were identified in the same high school, TB contact
surveillance was conducted through an epidemiologic
investigation (Figure 1). Diagnosis of active TB cases was
confirmed by chest x-rays, sputum-smears using auramine
fluorochrome staining, and culture using solid (3% Ogawa)
and liquid (BACTEC MGIT 960, Becton Dickinson, Sparks,
MD, USA) media. Nucleic acid probes (Gen-Probe, San Diego,
CA, USA) were used to identifyM. tb complex from samples that
showed mycobacterial growth.
The TB contact investigation used QFT-GIT and chest X-
rays. High-resolution chest CT scans were performed in subjects
with positive IGRA results to help differentiate active TB from
LTBI. Initial screening by QFT-GIT in 158 close contacts who
were at high risk of infection diagnosed 9 active TB and 23 LTBI
cases. Following further testing of a total of 678 students and staff
at the school in November 2017, 13 contacts were diagnosed with
active TB and 41 with LTBI. Considering that QFT-GIT has a
window of conversion after exposure to M. tb (Anibarro et al.,
2011), a second QFT-GIT test was performed after 8 weeks in
126 close contacts with initially negative IGRA results. Seven
subjects had IGRA conversion, and one was confirmed to have
active TB. Two of 9 subjects with abnormal chest X-ray and
negative IGRA results were diagnosed with active TB; the
remaining six subjects were confirmed to have no abnormal
parenchymal lesion by chest CT, and one subject was diagnosed
with bacterial pneumonia and cured after antibiotic treatment. In
total, 28 patients with active TB and 70 individuals with LTBI
were diagnosed (Figure 1).
The TB patients were treated using the first line standard
regimen using rifampicin, isoniazid, ethambutol, and
pyrazinamide for 6-9 months. The LTBI contacts receivedMarch 2021 | Volume 11 | Article 599386
Hong et al. IGRA Containing Beijing/K Strain-Specific Peptidesprophylactic therapy with rifampicin and isoniazid for 3 months.
Based on the results of screening for M. tb infection, 70 contacts
with LTBI were advised to take prophylactic treatment. Among
69 subjects who started treatment, 59 successfully completed 3
months of treatment, and 10 discontinued treatment due to
elevated liver enzymes or change of mind. One student who
refused LTBI prophylaxis treatment progressed to active TB after
3 months and received anti-TB medication for 6 months. Of 43
LTBI subjects who participated in this study, 7 discontinued
prophylactic treatment. However, none has progressed to active
disease in the following 2 years.
Prior to anti-TB treatment, 25 active TB patients and 43 LTBI
contacts provided written informed consent for inclusion in the
present study, in accordance with the Declaration of Helsinki
(Figure 1). Consent of legal guardians was obtained if
participants were younger than 19 years. Subjects who agreed
to the follow-up study were enrolled after treatment, comprising
24 active TB and 30 LTBI subjects. Students who showed
negative IGRA results were not allowed to visit the hospital,
and 24 normal healthy controls who had no history of previous
M. tb exposure were recruited outside the school, as negative
controls. Since the healthy control group was not recruited from
TB outbreak cohort, age and gender distributions were not
similar to that of active TB and LTBI groups. Healthy controls
were older than patients with active TB and LTBI subjects
(median age: 38 in health controls, 18 in active TB, 18 in
LTBI). More females were included in the healthy control
group, compared with the active TB and LTBI subjects
(healthy controls: 83.3%, active TB:0%, LTBI: 2.3%). None of
the study participants had HIV, cancer or diabetes. The study
was approved by the Institutional Review Boards of Chuncheon
Sacred Heart Hospital (approval number: 2017-27).Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3Preparation of MTBK Antigen Tube
Including Beijing/K-Derived Peptides
Peptide antigens (without glycosylation) were designed based on
predicted epitope sites for major histocompatibility complex type II
binding; the predicted binding affinity was scored according to
different types of human leukocyte antigen, and the epitope sites
with highest scores were chosen from the database of SYFPEITHI
program (Rammensee et al., 1999). Peptides were synthesized with
> 95% purity (GenScript, NJ, USA) and each peptide stock (1mg/
mL) was dissolved in distilled water, following in RPMI1640 media
for working solution. The MTBK antigen tube was formulated with
peptides containing two dominant epitope sites, each from theM. tb
ESAT-6 (45 µg/mL), CFP-10 (45 µg/mL), and MTBK_24800 (10
µg/mL) proteins (Rammensee et al., 1999; Arend et al., 2000;
Aagaard et al., 2009; Hur et al., 2016) (Table 1). Nil tubes
including RPMI 1640 media only were also prepared.
Preparation of Blood Samples
Heparinized blood samples were collected in three QFT-GIT
tubes (QuantiFERON-TB Gold; Qiagen, Hilden, Germany) andTABLE 1 | Amino acid sequences of M. tb antigens.






76-99 RDGLVRDANNYEQQEQASQQILSSMarchPredicted dominant epitopes were selected from M. tb ESAT-6, CFP-10, and
MTBK_24800, and six different synthetic peptides were combined in a tube (MTBK).FIGURE 1 | Flowchart of M. tb infection screening during the TB outbreak and recruitment of study subjects. A total of 28 active patients with TB and 70 individuals
with LTBI were found based on contact screening tests for M. tb infection in 758 individuals. Among the contacts, 25 TB patients and 43 subjects with LTBI were
recruited for this study. Immune responses were followed up in 24 patients with TB and 30 subjects with LTBI after successful treatment. * MTBK antigen tubes
were used.2021 | Volume 11 | Article 599386
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peptides. The QFT-GIT and MTBK tubes with blood samples
were incubated upright at 37°C for 18-24 hours, and the
supernatants were harvested. All samples were stored at -70°C
until the end of subject recruitment.
QFT-GIT IFN-g Enzyme-Linked
Immunosorbent Assays (ELISA)
Harvested supernatants were utilized for IFN-g ELISA according
to the manufacturer’s protocol (QuantiFERON-TB Gold;
Qiagen, Hilden, Germany). Briefly, 50 µL of freshly prepared
conjugate solution, reconstituted standards, and harvested
plasma samples were loaded into 96-well microplates. The
microplates were incubated at room temperature for two
hours, and 100 µL of enzyme substrate solution was added to
each well after washing the microplates six times using diluted
wash buffer. Finally, 50 µL of enzyme stopping solution was
added with a 30-minute incubation at room temperature, and the
microplates were measured at 450 nm to obtain optical
density readings.
Multiplex Bead Array
Six analytes (IFN-a, IL-13, IL-17A, CXCL10, CCL5, TNF-a)
were simultaneously measured using a multiplex bead array kit
according to the manufacturer’s protocol (Merck Millipore,
Darmstadt, Germany). Assay plates were measured on a
Luminex100 machine (Luminex, Austin, TX, USA), and a
standard curve for each analyte was obtained using MasterPlex
QT 2010 software (Hitachi, San Bruno, CA, USA).
Molecular Genotyping of Clinical Isolates
M. tb isolates were obtained from 6 of 10 TB patients who
showed M. tb growth in culture and Beijing/K strain type
confirmed by polymerase chain reaction (PCR) (Warren et al.,
2004). Briefly, genomic DNA was extracted from each isolate,
and PCR was performed using Prime Taq polymerase (Genetbio
Inc., Daejeon, Korea) and primer sets to identify 4 particular
genotypes: Beijing (5’-GACIIICCGGGGCGGTTCA-3’, 5’-
CATGAACTCGCGGCTGTTTAGG-3’), Beijing/K (5’- GAC
IIICCGGGGCGGTTCA-3’, 5’-GGAGCGATGAACGACT
AGAGCAC-3’), Beijing/M (5’-CGTCGTGCCCGTATAACCG-
3’, 5’- GACIIICCGGGGCGGTTCA-3’), and Non-Beijing (5’-
GTGGTGAGACGCGTAGTTCG-3 ’ , 5 ’ -GTACGGCG
AAAGGTTTGAGC-3’). Sets were designed to determine
positive amplification of ~350bp, ~250bp, ~150bp, and
~500bp, respectively. PCR reaction mixtures were denatured at
95°C for 5 minutes, annealed at 62°C for 20 seconds, and
extended at 72°C for 30 seconds for 35 cycles. Negative control
did not include genomic DNA.
Statistical Analysis
An optimal cut-off point for positive IFN-g responses was
determined based on Youden’s index greater than 70% for
both sensitivity and specificity (Fluss et al., 2005). Diagnostic
accuracy and significance of immune responses were analyzed by
the area under the ROC curve (AUC), one-way ANOVA with
subsequent Kruskal-Wallis test, and Wilcoxon signed rank test.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4Agreement of the results between antigen tubes (MTBK vs. QFT-
GIT) was measured using Kappa statistics.RESULTS
Characteristics of Study Participants From
the School Outbreak Cohort
The general characteristics of participants are described in Table
2. Age and sex were similarly distributed between TB patients
and LTBI contacts. All participants had received childhood BCG
vaccination and had no other acute or chronic disease. Ten
(40%) of the TB patients were positive by respiratory specimen
culture, and 15 were diagnosed by radiologic and clinical criteria.
Most patients were diagnosed early after exposure, and few had
cavities or more than two-thirds chest field extension. All the TB
patients were treated with first-line anti-TB drugs for more than
6 months, and one with tuberculous pleurisy underwent surgical
pleural decortication. All the TB patients showed radiologic and
clinical improvement with negative culture results at completion
of therapy.
M. tb Genotypes of Clinical Isolates
Clinical isolates were obtained from 6 of 10 patients for whomM.
tb growth was confirmed in culture. Based on PCR analysis, the
M. tb Beijing (350 bp) and K (250 bp) genotypes were
demonstrated in all clinical isolates tested (Figure 2).
Change of QFT-GIT Test Outcomes at
Diagnosis and Enrollment
M. tb infection was diagnosed by QFT-GIT IGRA screening
during the contact investigation, and those with positive IFN-g
results were subsequently examined for diagnosis of active TB inTABLE 2 | Characteristics of study subjects from the school outbreak cohort.
Active TB (n=25) Latent TB (n=43)
Age† 18 (17-18) 18 (17-18)
Male 25 (100%) 42 (97.7%)
BMI (kg/m2)† 21.8 (19.7-24.2) 22.8 (20.6-25.4)
BCG vaccination 25 (100%) 43 (100%)
IGRA positivity 23 (92%) 43
Smear AFB positivity 1 (4%)
M. tuberculosis culture positivity 10 (40%)
Extrapulmonary TB 1 (4%)
Chest image at diagnosis
Cavity 2 (8%)
Centriolobular nodules 23 (92%)
Pleural effusion 1 (4%)
Extension of chest field
Less than one-third 23 (92%)
Less than two-thirds 0 (0%)
More than two-thirds 2 (8%)March 2021 | Volume 1The number of subjects for each feature is noted. All but one patient had pulmonary TB,
and only the patient with extrapulmonary TB showed AFB positive result at diagnosis. Ten
of 25 (40%) TB patients were confirmed to have M. tuberculosis growth by culture,
whereas most subjects (92%) showed positive IGRA results.
†Median (interquartile range IQR).
BMI, body mass index; AF, acid fast bacilli.1 | Article 599386
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participants including active TB patients were retested for M. tb
infection by QFT-GIT during recruitment, and the two test
outcomes were analyzed. Reversion of IFN-g results was
observed in four contacts in the LTBI group during the 3-5
weeks between the initial IGRA screenings and retesting at
recruitment (Supplementary Figure 1). In contrast, only one
patient showed IGRA conversion. All the IFN-g values with
outcome differences were less than 0.7 IU/mL, except for one
LTBI contact who had a value of 5.03 IU/mL IFN-g at diagnosis
(Supplementary Figure 1).
IFN-g Responses to MTBK Antigen
MTBK antigen comprised of 6 peptides, including two dominant
epitopes from each of MTBK_24800, ESAT-6, and CFP-10 (Table
1). IFN-g responses to the MTBK antigen differentiated between
non-infected control and both infected groups, LTBI and active TB
(P<0.01 and P<0.001, respectively) (Figure 3A). The optimal cut-off
value for IFN-g positivity was 0.065 IU/ml IFN-g, which had 79%
sensitivity (68% < 95% CI < 88%) and 71% specificity (49% < 95%
CI < 87%). Based on this positive cut-off point (> 0.065 IU/ml),
approximately 77% (33 of 43) of the contacts showed positive IFN-g
responses, and the positive rate was slightly higher in TB patients
than in contacts with LTBI (83%; 19 of 23 patients). The AUC value
for detecting LTBI was 0.76 (0.64 < 95% CI < 0.88, P<0.001), but the
diagnostic accuracy was increased in TB patients (AUC = 0.91, 0.83
< 95% CI < 0.99, P<0.001) (Figures 3B, C, respectively). TheMTBK
antigen-specific IFN-g responses also differentiated between active
TB and LTBI (AUC = 0.73, 0.60 < 95% CI < 0.86, P<0.001) (Figures
3A, D).
Comparative Analyses of IFN-g Responses
Between the Two Sets of Antigen Tubes
Based on the rates of IFN-g positivity and negativity, total
concordance of the results between the MTBK antigen tube
and the QFT-GIT antigen tubes was about 81% (kappa=0.23,
positive agreement: 89%, negative agreement: 32%). Among 68
enrolled subjects, 13 (3 patients and 10 individuals with LTBI)Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5showed different results to the two antigen tubes. Two of 5
subjects with negative IFN-g responses by QFT-GIT showed
positive results in the IFN-g ELISA using the MTBK antigen.
Multiple Cytokine Responses to Beijing/
K-Peptide Combination
To test whether cytokines other than IFN-g might provide
improved diagnostic accuracy, additional six cytokines and
chemokines were assayed in the culture supernatants. None of
the cytokine and chemokines tested (IFN-a, IL-13, IL-17,
CXCL10, CCL5, and TNF-a) differentiated between active TB
and LTBI, unlike IFN-g in response to the MTBK antigen.
However, IL-13 and CXCL10 responses were significantly
higher in infected contacts than healthy controls (Figure 4).
Diagnostic accuracy was better at identifying active TB than
LTBI for both IL-13 and CXCL10 responses (AUC: 0.83 vs. 0.69
for IL-13, 0.90 vs. 0.79 for CXCL10, P<0.001). IFN-a, IL-17A,
CCL5 and TNF-a responses to the MTBK antigen did not vary
between the healthy controls and M. tb infected groups
(Figure 4).
Immune Responses With or Without
Antigen Stimulation Following TB
Treatment
The IFN-g, IFN-a, IL-13, IL-17, CXCL10, CCL5, and TNF-a
responses were followed in 24 patients who finished TB
treatment. A significant decrease (P<0.05) of the IFN-g
response was found after TB treatment although IFN-g values
did not revert to negative in most patients (Figure 5). The
proportion of strong IFN-g (≥ 1.5 IU/mL) responders was
reduced, and about 75% of responders had low IFN-g
responses (≤ 1.0 IU/mL) after TB treatment. The other six
analytes did not show significant changes in response to the
antigenic stimulation. However, spontaneous TNF-a (P<0.01)
release was significantly reduced after TB treatment (Figure 6).
The proportion of responders with spontaneous high levels of
TNF-a release was also decreased with therapy, whereas more
patients had weak positive TNF-a responses (Figure 6).FIGURE 2 | M. tb genotypes in clinical isolates. M. tb genotypes were confirmed by PCR in 6 of 10 patients who showed M. tb growth in culture. All clinical isolates
were Beijing/K strains of M. tb. M: 100 bp DNA ladder, Lane 1: Beijing strain (~ 350 bp), Lane 2: K strain (~ 250 bp), Lane 3: M strain (~ 150 bp), Lane 4: Non-
Beijing strain (~ 500 bp), Lane 5: negative control.March 2021 | Volume 11 | Article 599386
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TB is one of the top 10 causes of death and the leading cause
from a single infectious agent (WHO, 2019). The End-TB
strategy of WHO to end the global TB epidemic focuses on
early detection, treatment, prevention, and intensified research
including development of effective vaccines (WHO, 2015). InFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 6South Korea, BCG vaccination is strongly recommended after
birth, but the value of the BCG vaccine is limited by insufficient
protection against pulmonary TB and by variable efficacy against
different M. tb strains reported in diverse geographic locations
(Kaufmann et al., 2015). Therefore, there would be clinical value
in developing an intervention strategy or new diagnostic tool by
focusing on the highly virulentM. tb strains found in regional TBFIGURE 4 | Measurement of multiple cytokine responses to Beijing/K-combination. Among IFN-a, IL-13, IL17, CXCL10, CCL5, and TNF-a, the IL-13 and CXCL10
responses were significantly higher in LTBI and active TB compared with HC (antigen minus nil). However, disease status (active TB vs. LTBI) was not differentiated
by the cytokine/chemokine responses. The median responses are marked by red lines. *P < 0.05, ***P < 0.001 by one-way ANOVA with subsequent Kruskal-Wallis
test, HC, healthy control.A B
C
D
FIGURE 3 | IFN-g responses to the Beijing/K-peptide combination and diagnostic accuracy of identifying M. tb infection. IFN-g responses to MTBK antigen were
significantly higher in active TB and LTBI compared with HC. M. tb infection and disease status were differentiated by IFN-g responses. The median value of IFN-g is
marked in red, and a dotted line represents the cut-off for positive results (0.065 IU/mL) (A). Immune responses to the MTBK antigen had good diagnostic values
(AUC > 0.7) for distinguishing between active TB and LTBI (D), as well as between infected and non-infected individuals (B, C). *P < 0.05, **P < 0 .01, ***P < 0.001
by one-way ANOVA with subsequent Kruskal-Wallis test, HC, healthy control.March 2021 | Volume 11 | Article 599386
Hong et al. IGRA Containing Beijing/K Strain-Specific Peptidesoutbreaks. In this study, all the tested clinical isolates had a
Beijing/K genotype, supporting the previous finding that the
Beijing/K genotype of M. tb is most frequently associated with
TB outbreaks in South Korea (Kim et al., 2001). IFN-g responses
to the MTBK antigen were significantly higher in TB contactsFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 7than healthy controls, and also differentiated between active TB
and LTBI. Diagnostic accuracy was demonstrated by an AUC
value (> 0.7) that distinguished M. tb infection from healthy
controls and defined disease status (active TB vs. LTBI). Anti-TB
treatment resulted in reduced MTBK antigen-specific IFN-gA B
C
FIGURE 6 | Treatment efficacy measured by TNF-a. TNF-a concentration (nil) was significantly reduced after TB treatment (A, B). The proportion of responders
with a high level of TNF-a decreased, while that of responders with a low level of TNF-a dramatically increased (C). The horizontal red line represents the median
value of TNF-a. ***P < 0.001 by Wilcoxon signed rank test, Tx, treatment.A
B
FIGURE 5 | Follow-up immune responses to the Beijing/K-peptide combination after TB treatment. (A) Distribution of cytokines and chemokines as immune responses
to the Beijing/K-peptide combination after TB treatment. The median responses are marked by red lines. (B) Longitudinal analysis of cytokine and chemokines after TB
treatment. Significant decreases in IFN-g response to the MTBK antigen were observed in 24 TB patients who finished anti-TB treatment. Other cytokines and
chemokines tested in this study did not show significant changes after treatment (antigen minus nil). *P < 0.05 by Wilcoxon signed rank test, Tx, treatment.March 2021 | Volume 11 | Article 599386
Hong et al. IGRA Containing Beijing/K Strain-Specific Peptidesresponses and decreased plasma TNF-a production. These
results suggest that measurement of IFN-g induced by the
MTBK peptides may have promise as a TB diagnostic assay
and may improve the current IGRA based on ESAT-6 and
CFP-10.
Delayed identification of the index case seemed to cause the
primary case in September, resulting in rapid transmission of
infection with prolonged contact within the school. AFB staining
of sputa is generally utilized but does not distinguish betweenM.
tb and NTMs (TDIUATLD, 2005). M. tb growth can be
confirmed by culture, but it takes at least 4 weeks to achieve
results unless a faster molecular assay such as GeneXpert is used
(TDIUATLD, 2005). In this study, only one patient showed a
positive AFB smear result at the early diagnosis time point, and
culture positivity was later identified in about 40% of patients.
However, 92% (23 of 25) of the TB patients showed positive IFN-
g responses at the time of initial screening, indicating that the
blood test may help in early diagnosis of TB in those with
negative AFB results.
The QFT-GIT is a very important recent advance in TB
diagnostics although it does not have sufficient value to
differentiate between active TB and LTBI or to predict treatment
efficacy and disease cure (Clifford et al., 2015). Moreover, it is not
robust enough to diagnose M. tb infection at borderline cut-off
ranges (Metcalfe et al., 2013; Jonsson et al., 2017). IGRA
conversion and reversion were also found in this study, in which
two individuals whose IGRA reverted had values close to the cut-
off point, supporting that the QFT-GIT test outcome is not
confirmatory near the cut-off point. This suggests the need for a
new generation of IGRAs with additional or alternative antigens
and cytokines/chemokines. A recent prospective study
demonstrated greater than 80% sensitivity and specificity for
detecting active TB using IGRAs with the M. tb Rv3615c and
Rv3879c antigens (Whitworth et al., 2019). An ESAT-6-free IGRA
antigen cocktail had good diagnostic performance in a high TB
burden area (Nemes et al., 2019), indicating that it might be
considered as an assay for diagnosis in trials with future ESAT-6-
containing vaccines. Our data showed that MTBK_24800 peptides
with ESAT-6 and CFP-10 which are main antigens of QFT-GIT
differentiated between active TB and LTBI.
IFN-g is strongly associated with protective immunity against
TB, but many other cytokines and chemokines are also crucial
for control of M. tb infection. In the early response to M. tb,
TNF-a synergizes with IFN-g to activate macrophages and
eliminate ingested bacteria (Zuñiga et al., 2012). With
increased production of Th2 cytokines, IL-13 inhibits
autophagy-dependent killing of M. tb (Deretic et al., 2009),
whereas pro-inflammatory IL-17 participates in granuloma
formation by recruiting activated neutrophils (Okamoto et al.,
2010). CXCL10 has good diagnostic value for detecting active TB
in children and adults, but it does not distinguish between active
TB and LTBI similar to IFN-gmeasured by QFT-GIT (Whittaker
et al., 2008). Recently, CXCL10 has been suggested as a
biomarker for monitoring pulmonary TB along with CCL5
(Zhao et al., 2018). In this study, significantly higher IL-13 andFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 8CXCL10 responses were found in M. tb-infected groups
compared with healthy controls whereas only IFN-g
differentiated between active TB and LTBI. The IFN-g
responses were also significantly decreased with reduced TNF-
a concentrations in cured TB patients. These findings suggest
that IFN-g is the most robust biomarker for identifying M. tb
infection in response to the Beijing/K peptide combination,
whereas the spontaneously released plasma TNF-a may predict
treatment efficacy or disease cure. Based on the report that IFN-a
production is related to the virulence of an M. tb strain (Manca
et al., 2001), it is expected that the IFN-a responses might be
significantly different in ESAT-6/CFP-10 free cocktails
containing only peptides from Beijing/K-specific antigens.
This study has some shortcomings, that could be addressed in
future TB outbreaks. Firstly, not all the TB patients were positive
by the gold-standard M. tb culture, and as a result M. tb isolates
were not available from all the tested TB patients to confirm that
they were infected with the same Beijing strain of M. tb.
Secondly, due to limited blood samples, the new MTBK_24800
peptides were not tested on their own, but only in combination
with peptides from ESAT-6 and CFP-10. The improved
diagnostic potential of this peptide mix can now be dissected
further using MTBK_24800 peptides on their own in
comparison with the selected ESAT-6 and CFP-10 peptides.
Although the MTBK antigen differentiated between active TB
and LTBI, there is no evidence which the MTBK antigen
improved the diagnostic performance of QFT-GIT test in this
study. For the comparison, two types of antigen tubes should be
prepared (MTBK_24800 with the antigens of QFT-GIT vs. QFT-
GIT alone).
The relatively low cut-off point (0.065 IU/ml, > 70%
sensitivity and specificity) for MTBK-specific IFN-g and the
overlapping values between the healthy control and LTBI
groups should be examined further to meet the required
standard for clinical use. In particular, although an unrelated
group of adult healthy controls were used, not from the school
where the outbreak occurred, additional testing in healthy
Korean controls is needed. A newer generation of
QuantiFERON test (QFT-Plus) contains ESAT-6, CFP-10 and
several peptides to stimulate both CD4- and CD8 T cells. The
sensitivity of QFT-Plus in active TB patients was 1.3% higher,
compared with QFT-GIT, suggesting that more epitope peptides
in QFT-Plus antigen may get higher IFN-g levels (Oh et al.,
2020). Thus upgraded antigen cocktails including additional
epitopes from MTBK_24800, optimization of the peptide
concentrations, and ESAT-6/CFP-10 free peptide cocktails
should be prepared and tested in further prospective cohort
studies with a large number of patients. However, to the best of
our knowledge, this is the first study to report screening forM. tb
infection using an IGRA with an antigen derived from a
predominant M. tb outbreak strain (Beijing/K) in a TB
outbreak cohort. The immune signature of the IGRA may
therefore provide useful information for the development of
improved TB diagnostics and vaccines where the Beijing/K strain
of M. tb is endemic.March 2021 | Volume 11 | Article 599386
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